Investors
Information for investors including share information, share analysis, shareholder news and annual reports.
Q1 2013 results: 24 Apr 2013
View Q1 results details and CFO video
Press releases
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
GSK and Save the Children form unique partnership to save the lives of one million children
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.

| GlaxoSmithKline plc |
Tel: 020 8047 5000 |
| 980 Great West Road |
Fax: 020 8047 7807 |
| Brentford |
|
| Middlesex TW8 9GS |



